Animal Models of Diet-induced Hypercholesterolemia by Chan, Jeannie et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Animal Models of Diet-induced Hypercholesterolemia
Jeannie  Chan, Genesio M. Karere, Laura A. Cox and
John L. VandeBerg
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/59610
1. Introduction
Cholesterol is a component of the cell membrane and metabolites of cholesterol, such as bile
acids, steroid hormones and vitamin D, serve important biologic functions in vertebrates.
Cholesterol is synthesized primarily in the liver and transported to cells throughout the body
by lipoproteins via the blood, even though all nucleated cells in the body are capable of
synthesizing cholesterol. Whole-body cholesterol homeostasis is determined by cholesterol
absorption, cholesterol synthesis and cholesterol excretion, and losing control of any of these
processes leads to an increase in plasma cholesterol. Liver and intestine are the major sites that
control cholesterol homeostasis. The liver synthesizes cholesterol for secretion in nascent
lipoproteins when blood levels of cholesterol are low, and removes excess cholesterol from the
blood by taking up chylomicron remnants, high density lipoprotein (HDL), very low density
lipoprotein (VLDL) and low density lipoprotein (LDL) particles. It converts cholesterol into
bile acids, and secretes cholesterol and bile acids into bile for elimination from the body. The
intestine regulates influx of cholesterol from the lumen and efflux of cholesterol back into the
lumen to control the amount of cholesterol that enters the body [1].
Hypercholesterolemia is characterized by LDL cholesterol exceeding 159 mg/dl [2]. Many
developed countries have a high prevalence of hypercholesterolemia. According to an estimate
based on data from the 2005-2008 National Health and Nutrition Examination Survey, the
Centers for Disease Control and Prevention reported that 33.5% of US adults aged 20 or older
had high levels of LDL cholesterol [3]. Diets containing high levels of cholesterol and high
levels of fat (HCHF) are frequently the culprit in causing hypercholesterolemia. In addition,
genetic factors influence susceptibility to diet-induced hypercholesterolemia.
Hypercholesterolemia is a complex disorder often due to multiple genetic defects and rarely
due to a single genetic defect as in the case of familial hypercholesterolemia [4]. Because
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hypercholesterolemia is associated with risk of developing atherosclerosis, much research has
been devoted to understanding the genetic variants and environmental factors that contribute
to elevated blood LDL cholesterol. There are several challenges to investigating gene-diet
interactions in humans. It is difficult to control the diet and environment of human subjects
for long periods of time, and ethical constraints limit access to tissue samples. These problems
can be circumvented by using animals to study the effects of diets on cholesterol homeostasis
and atherosclerosis because animals can be fed the same diet and kept under the same
laboratory conditions for long periods of time, and because access to tissue samples from
animals is less restricted. Numerous animal species have been used as animal models for
investigating hypercholesterolemia, including rabbits [5,6], mice [7], guinea pigs [8], minipigs
[9], laboratory opossums [10] and nonhuman primates [11-15]. Nonhuman primates are more
similar to humans than other animals, but ethical issues, facilities and high cost limit studies
with nonhuman primates. Non-primate animal models have other limitations. However,
extensive use of the collage of primate and non-primate models has provided considerable
insights into the genes and molecular mechanisms that control plasma cholesterol in response
to diets.
In this chapter, we discuss mouse, laboratory opossum and nonhuman primate models of
hypercholesterolemia. Mice lipoprotein profiles differ from humans and they are resistant to
developing hypercholesterolemia and atherosclerosis, but genetic engineering tools have been
used effectively to alter their lipoprotein profiles. A commonly used mouse model in which
the apolipoprotein E gene (apoE) is disrupted exhibits a lipoprotein profile similar to that of
humans. In addition, apoE knockout mice become hypercholesterolemic and have a propensity
to develop atherosclerosis [16,17]. Mice have also been used extensively to elucidate mecha‐
nisms that regulate cholesterol homeostasis. Cholesterol excretion is one of the major processes
that can be targeted to reduce hypercholesterolemia. A nonbiliary pathway for disposal of
cholesterol termed transintestinal cholesterol excretion (TICE) was first described in mice
almost a decade ago [18]. A growing body of evidence for TICE has since been gathered using
genetically modified and normal mice [19,20]. The discovery of TICE has opened a new avenue
of research into the role of the intestine in cholesterol excretion [21].
The laboratory opossum is a model of diet-induced hypercholesterolemia developed at Texas
Biomedical Research Institute that does not require genetic manipulation to knock out or
overexpress specific genes to elevate LDL cholesterol [22,23]. Through many generations of
inbreeding and selection for plasma cholesterol response to an HCHF diet, high and low
responding strains of opossums were produced. All strains have normal levels of plasma
cholesterol on a basal diet. However, high responding opossums exhibit an extremely high
LDL cholesterol response when fed an HCHF diet compared to low responding opossums.
Hypercholesterolemia in high responding opossums is caused by mutations in at least two
genes. One of the causative genes has been identified as ABCB4; mutations in the ABCB4 gene
impair biliary cholesterol secretion [24]. The ABCB4 gene has not been shown previously to be
associated with hypercholesterolemia. The opossum model provides an opportunity to
investigate genes that interact with ABCB4 to regulate cholesterol homeostasis.
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Nonhuman primates are utilized as models of hypercholesterolemia because of their physio‐
logic and genetic similarities with humans [25]. In addition, nonhuman primates naturally
develop hypercholesterolemia and atherosclerosis, both of which can be exacerbated by HCHF
diets to mimic diet-induced hypercholesterolemia and atherosclerosis in humans [11,15,26].
Because of these characteristics, nonhuman primates including baboon (Papio hymadryas),
rhesus macaque (Macaca mulatta), green monkey (Chlorocebus aethiops) and cynomolgus
monkey (Macaca fascicularis) have been used as animal models for biomedical research aimed
at understanding diet-induced hypercholesterolemia in humans. Nonhuman primates exhibit
species and individual variations in plasma cholesterol in response to HCHF diets. Studies
using pedigreed baboons and high-throughput sequencing technology have identified genetic
factors that influence plasma cholesterol response to HCHF diets [13,27].
2. Mouse models
2.1. Mouse models of cholesterol metabolism
Mouse models are the most widely used animal models because of several advantages such
as ease of breeding, large litter size, a short generation time of 9 months and economies of
colony maintenance. An additional advantage of mice is the availability of tools to add
exogenous genes to the germ line to create transgenic mice, or to disrupt endogenous genes
by homologous recombination in murine embryonic stem cells to create knockout mice.
Although there are important differences between mice and humans in lipoprotein and
cholesterol metabolism, genetic manipulation has provided mouse models that resemble some
aspects of hypercholesterolemia in humans.
Non-genetically modified mice have high levels of HDL cholesterol and low levels of LDL
cholesterol, whereas humans have high levels of LDL cholesterol and low levels of HDL
cholesterol. The difference in lipid profiles between mice and humans is due to absence of the
cholesteryl ester transfer protein (CETP) in mice [28,29]. CETP is an enzyme that transfers
cholesterol ester from HDL to VLDL and LDL in exchange for triglycerides [30]. In normal
mice lacking CETP, more than 80% of plasma cholesterol is carried on HDL, so mice with high
levels of HDL cholesterol are resistant to hypercholesterolemia and atherosclerosis. To
overcome this problem to using mice as models for research aimed at understanding choles‐
terol metabolism in humans, several genetically engineered strains of mice were generated to
alter the distribution of plasma cholesterol from HDL to VLDL and LDL. The genetically
modified mice include CETP transgenic, apoE knockout and LDL receptor knockout mice.
CETP transgenic mice. Transgenic mice carrying human and cynomolgus monkey versions of
the CETP gene were studied to investigate the effects of CETP on distribution of plasma
lipoprotein cholesterol. Transgenic mice expressing high levels of human CETP showed a
small decrease in HDL cholesterol and a small increase in VLDL and LDL cholesterol on the
basal (chow) diet [29]. Transgenic mice expressing high levels of cynomolgus monkey CETP
showed greater responsiveness than nontransgenic mice when challenged with an HCHF diet.
Total plasma cholesterol of CETP transgenic mice averaged 250 mg/dl whereas those of
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nontransgenic mice averaged 163 mg/dl. Furthermore, CETP transgenic mice showed that
CETP activity was inversely associated with apoA-I, but positively associated with apoB [28].
These observations demonstrated that human and monkey CETP can interact with mouse
lipoproteins to mediate its effects in lipoprotein metabolism.
ApoE deficient mice. ApoE is a 34 kD glycoprotein produced primarily in the liver and to a lesser
extent in other tissues. With the exception of LDL particles, apoE is a structural component of
all lipoprotein particles and chylomicrons. It binds to the LDL receptor and to the LDL
receptor-related protein to remove VLDL and chylomicron remnants from the plasma [31].
Using gene targeting to disrupt the apoE gene, mutant mice developed severe hypercholes‐
terolemia as expected from a defect in lipoprotein clearance from plasma. Total plasma
cholesterol levels were highly elevated in homozygous apoE deficient (apoE-/-) mice (400-500
mg/dl) compared with normal mice (80 mg/dl) on a chow diet with 0.01% cholesterol and 4.5%
fat. A more dramatic increase in plasma cholesterol was observed in apoE-/- mice (1800 mg/dl)
fed an HCHF diet with 0.15% cholesterol and 20% fat. Plasma cholesterol concentrations in the
VLDL and intermediate density lipoprotein (IDL) fractions were increased on both diets. The
apoE-/- mice were highly susceptible to atherosclerosis, even on chow diet, as a result of the
increase in plasma cholesterol concentrations [16,17].
LDL receptor deficient mice. The LDL receptor is a cell surface receptor expressed in many cell
types. In the liver, the LDL receptor regulates plasma cholesterol by binding to apoB and apoE
on the surface of lipoprotein particles and removes these particles from the plasma [32].
Patients with familial hypercholesterolemia [33] and Watanabe-heritable hyperlipidemic
rabbits [34] develop elevated levels of LDL cholesterol due to mutations in the LDL receptor.
Based on this knowledge, LDL receptor knock out (LDLR-/-) mice were generated to increase
plasma LDL cholesterol concentrations. The loss of functional LDL receptors elevated total
plasma cholesterol in LDLR-/- mice, but the effect was more moderate compared to apoE-/-
mice. The mean total plasma cholesterol on a chow diet was 293 mg/dl and on a diet enriched
with cholesterol (0.2%) and fat (19%) was 425 mg/dl. The increase in plasma cholesterol in
LDLR-/- mice was attributed to increases in IDL and LDL cholesterol [35]. Compared with
familial hypercholesterolemia patients (receptor-negative homozygotes) who have plasma
cholesterol levels over 700 mg/dl, the effect of LDL receptor deficiency is less severe in mice.
This is due to the fact that mice produce VLDL particles containing both apoB-48 and apoB-100,
whereas humans only produce VLDL particles containing apoB-100 [36]. In mice, VLDL
particles containing apoB-48 can be cleared from the plasma by the chylomicron remnant
receptor in addition to the LDL receptor, so fewer VLDL particles are converted to LDL
particles. Therefore, LDL receptor deficiency in mice does not increase plasma cholesterol to
the same extent as in humans.
2.2. Mouse models of atherosclerosis
Disruption of the apoE gene causes hypercholesterolemic apoE knockout mice to develop
atherosclerotic lesions spontaneously [16,17]. Foam cell lesions were observed in chow-fed
apoE-/- mice 10 weeks after birth and the lesions progress to fibrous plaques by 20 weeks of
age. An HCHF diet accelerates all stages of lesion formation and increases the size of lesions;
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thus, formation of atherosclerotic lesions in apoE-/- mice is responsive to diet as in humans.
Because of the short period of time for lesion formation in apoE-/- mice, they have been used
extensively to study dietary and genetic factors affecting atherosclerosis and mechanisms of
atherogenesis, as well as to assess efficacy of pharmacologic agents on lesion size. Progression
of early lesions to advanced lesions in apoE-/- mice is similar to that in humans; lesions often
develop at vascular branch points and progress rapidly to foam cells with fibrous plaques and
necrotic lipid cores [37]. The major difference from humans is a low incidence of ruptured
plaques that leads to thrombosis and arterial occlusion. Plaque rupture is the event that causes
a heart attack in humans. A higher incidence of ruptured plaques was obtained by feeding a
diet enriched with 0.15% cholesterol and 21% fat to apoE-/- mice. After 8 weeks of feeding the
HCHF diet to apoE-/- mice, acute plaque ruptures were observed in the brachiocephalic arteries
of more than half of the animals [38].
2.3. Mouse models of cholesterol excretion
Hepatobiliary cholesterol excretion. The human body cannot degrade cholesterol, but it can
convert cholesterol to bile acids in the liver. Fecal excretion is the major route for the body to
remove cholesterol as bile acids or neutral sterols (cholesterol and its metabolites formed by
bacteria in the intestine). Diet-induced hypercholesterolemia can be mitigated by increasing
the loss of cholesterol in feces. Fecal excretion of cholesterol and bile acids depends on
transporting these molecules from the liver into bile. The ABCG5/G8 [39] and ABCB11 [40]
proteins transport cholesterol and bile acids, respectively. The ABCB4 protein transports
phospholipids (mainly phosphatidylcholine), which is essential for secretion of cholesterol
into bile [41,42]. ABCB11 plays a central role in hepatobiliary secretion as bile flow is the driving
force for biliary secretion of cholesterol and phospholipids [43].
Many studies have been carried out using transgenic and knockout mouse models to further
our knowledge of the physiologic pathways and molecular mechanisms that control choles‐
terol excretion. Transgenic mice expressing the human ABCG5 and ABCG8 genes directed by
their own regulatory DNA sequences (hG5G8Tg mice) had higher levels (5-fold) of biliary
cholesterol and higher levels (3- to 6-fold) of fecal neutral sterol compared with nontransgenic
mice, providing evidence that ABCG5 and ABCG8 function as cholesterol transporters [44].
Moreover, cholesterol absorption in these transgenic mice was reduced by 50% because the
proteins encoded by ABCG5 and ABCG8 genes are also expressed in the small intestine and
they transport cholesterol from the intestine into the lumen [44]. In another study, Abcg5 and
Abcg8 double knockout (G5G8-/-) mice were created to investigate the effects of disrupting
these genes on biliary cholesterol secretion. G5G8-/- mice were more diet-responsive than
normal mice on a 2% cholesterol diet. Plasma cholesterol increased 2-fold in G5G8-/- mice, but
not in normal mice. Hepatic cholesterol was markedly increased in G5G8-/- mice (18-fold)
compared with normal mice (3-fold). Accordingly, expression of the cholesterol synthesis
genes HMG-CoA synthase and HMG-CoA reductase was lower in G5G8-/- mice than normal
mice. Fecal neutral sterol was reduced by 36% in G5G8-/- mice relative to that in normal mice.
The findings using double knockout mice also supported ABCG5 and ABCG8 function in
cholesterol transport [45].
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Another series of experiments was conducted to investigate the role of phospholipids in
secretion of biliary cholesterol. Disruption of the Abcb4 (also known as Mdr2) gene in mice led
to a severe liver disease. Phospholipids were undetectable in the bile of homozygous Abcb4
knockout (Abcb4-/-) mice, while the levels in heterozygous Abcb4 knockout (Abcb4+/-) mice
were half of those in nontransgenic mice. Interestingly, Abcb4-/- mice secreted extremely low
levels of cholesterol into bile, but cholesterol levels in flowing bile from Abcb4+/- mice were
similar to those in nontransgenic mice [41]. Langheim et al. [46] investigated whether overex‐
pression of ABCG5 and ABCG8 could restore biliary cholesterol secretion in Abcb4-/- mice by
breeding Abcb4-/- mice with hG5G8Tg mice to generate Abcb4-/-;hG5G8Tg mice. The
Abcb4-/-;hG5G8Tg mice also secreted very low levels of biliary cholesterol, which were similar
to the levels in Abcb4-/- mice. Taken together, these results indicate that biliary cholesterol
secretion requires a minimal concentration of phospholipids in the bile. Biliary phospholipid
secretion in the liver serves two purposes. One is to protect the canalicular membrane of
hepatocytes exposed to high concentrations of bile acids from damage by the detergent action
of bile acids. Secretion of phospholipids by the liver into the bile reduces bile salt micelles to
extract phospholipids from the membranes of hepatocytes. The other is to make phospholipids
available for incorporation into pure bile salt micelles to form bile salt mixed micelles.
Solubility of cholesterol in bile salt mixed micelles is greater than that in pure bile salt micelles,
thus phospholipid secretion prevents formation of gallstones [47].
Nonbiliary cholesterol excretion. Hepatobiliary secretion is known to be the main pathway for
eliminating cholesterol from the body, but an increasing body of evidence suggests that plasma
cholesterol is also eliminated by a nonbiliary pathway in mice. As mentioned above, G5G8-/-
mice did not show a dramatic reduction in fecal neutral sterol excretion despite they had
extremely low levels of biliary cholesterol. Normal or even increased fecal neutral sterol
excretion was observed in other mouse models (Abcb4-/-, Npc1l1-LiverTg) that are severely
impaired in hepatobiliary cholesterol secretion [20]. This observation suggests the existence of
an alternate route, known as TICE, which does not involve biliary cholesterol secretion. Plasma
cholesterol is transported via blood to intestinal cells and eventually secreted into the intestinal
lumen for disposal in feces [20]. It should be mentioned that a nonbiliary cholesterol excretion
pathway has also been postulated to explain fecal neutral sterol loss in bile-diverted dogs [48,
49] and bile-diverted rats [50].
Intestinal perfusion studies [19] and in vivo stable isotope studies [51] in mice that have an
intact hepatobiliary secretion and enterohepatic cycling system revealed that TICE accounted
for ~30% of fecal cholesterol excretion. The site of action of TICE is the proximal small intestine
[19,52]. It is thought that TICE involves plasma lipoproteins to deliver cholesterol to the
intestine, then cholesterol is taken up by receptors at the basolateral membrane of enterocytes
and traverses the enterocytes to the apical membrane where it is excreted into the intestinal
lumen. There are still many gaps in our understanding of the molecular mechanism of TICE.
HDL is ruled out as the lipoprotein that delivers cholesterol to the intestine because TICE was
not diminished in Abca1 knockout mice having extremely low concentrations of plasma HDL
[53,54]. Evidence to support VLDL remnants or LDL as the plasma cholesterol carrier came
from studies using antisense oligonucleotides (ASO) to knockdown expression of proteins
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critical for production of VLDL and alter plasma VLDL cholesterol concentrations. ASO-
mediated knockdown of acyl-CoA:cholesterol acyltransferase activity 2 (ACAT2) in mice fed
a high cholesterol diet resulted in an increase in both VLDL cholesterol and fecal neutral sterol
excretion [55]. Conversely, ASO-mediated knockdown of microsomal triglyceride transfer
protein resulted in a decrease in both VLDL cholesterol and fecal neutral sterol excretion [56].
As for the receptor that takes up cholesterol at the basolateral membrane, it is not likely to be
the LDL receptor nor scavenger receptor BI (SR-BI) because neutral sterol excretion was not
affected in LDLR-/- mice [57] and SR-BI-/- mice [58,59]. It may involve other members of the
LDL receptor or a novel receptor. Lastly, Abcg5/Abcg8 and Abcb1 participate in the secretion
of cholesterol from enterocytes into the intestinal lumen [57].
A study in patients with complete biliary obstruction revealed they still excreted substantial
amounts of neutral sterol into feces [60]. Data from these patients showed that ~20% to 30% of
neutral sterols were excreted by TICE, which is similar to that excreted by TICE in normal
mice. However, the relevance of TICE for disposal of cholesterol in humans without biliary
obstruction has yet to be established. A recent ex vivo study showed that human and mouse
intestinal (duodenual) explants mounted on Ussing chambers were capable of effluxing
cholesterol, providing evidence for the activity of TICE in humans [57].
3. Laboratory opossum model
3.1. Characteristics of laboratory opossums
The gray short-tailed opossum (Monodelphis domestica) is a docile, nocturnal marsupial native
to Brazil and adjacent countries. It is the only marsupial species that has adapted to breeding
in captivity to produce large numbers of animals [61]. In addition to being able to breed in
captivity throughout the year, Monodelphis have a short generation time of 6 months and
produce large litters (typically 6-13). Breeding colonies have been established in the United
States, Brazil, Germany, United Kingdom, Japan, and Australia. Opossums in captive colonies
are quite different genetically from their wild counterparts due to selection that has undoubt‐
edly taken place while the animals were bred in isolated colonies for many generations;
therefore laboratory stocks of this species are referred to as laboratory opossums. Adult
laboratory opossums weigh 70-150 g, which is intermediate between mice (20-30 g) and rats
(250-300 g). They are maintained in polycarbonate rodent cages, and the standard laboratory
diet is commercial pelleted fox food provided ad libitium. Owing to its physical characteristics
as a laboratory animal and economic production in captivity, Monodelphis domestica has become
the most widely used marsupial in biomedical research. Furthermore, it was the first marsupial
species to have its genome sequenced and analyzed [62]. The availability of genome sequence
data has accelerated progress on genetic aspects of research involving Monodelphis.
The opossum model has advantageous characteristics for understanding cholesterol homeo‐
stasis. Monodelphis is omnivorous like humans, and its natural diet includes cholesterol derived
from the consumption of insects and small vertebrates. Therefore, laboratory opossums and
humans are likely to have many similarities in lipoprotein and cholesterol metabolism. Unlike
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genetically modified (transgenic and knockout) mouse models, the opossum model provides
an opportunity to identify naturally occurring variants of genes and to study how interactions
among gene variants lead to development of hypercholesterolemia. Some partially inbred
strains of opossums have inbreeding coefficients in excess of 0.95, and strains with high or low
responses to an HCHF diet have inbreeding coefficients in excess of 0.8. Since more than 80%
of the genes in each partially inbred strain have alleles that are identical by descent, the work
required to identify genes that cause diet-induced hypercholesterolemia in the opossum model
is substantially reduced.
3.2. Development of partially inbred strains
Nine wild-caught animals were imported from Brazil into the United States in 1978 by the
National Zoo in Washington, D.C. The founders of the breeding colony of laboratory opossums
at Texas Biomedical Research Institute were comprised of 20 first and second generation
descendants of those nine founders, together with 17 additional wild-caught opossums from
Brazil and two from Bolivia. After several generations of inbreeding, some individuals were
fed a high cholesterol (0.6% by weight) and high fat (17% by weight) diet for 6 months, and
total blood cholesterol was measured after an overnight fast. Low and high responses were
observed among opossums, with few animals exhibiting an intermediate response, i.e. the
phenotypes are clustered at the high and low ends of the range. Low responding opossums
had blood cholesterol levels ranging from 62-171 mg/dl whereas high responding opossums
had levels of 215-932 mg/dl [22]. Furthermore, analysis of lipoprotein particles by gradient gel
electrophoresis showed elevated levels of LDL particles in high responding opossums [22].
Subsequently, inbreeding and selection for either low responsiveness or high responsiveness
to the HCHF diet led to development of two related low responding partially inbred strains
(designated ATHE and ATHL) and a high responding partially inbred strain (designated
ATHH) that show extreme difference (>5-fold) in plasma cholesterol concentrations in
response to the HCHF diet. These strains are being used to identify genetic variants and
molecular mechanisms that cause diet-induced hypercholesterolemia.
3.3. Hypercholesterolemia in high responders
Dietary challenge and plasma cholesterol response. Studies were conducted to compare lipoprotein
characteristics of low responders from the ATHE strain and high responders from the ATHH
strain. The standard laboratory diet is the basal diet, which contains 0.04% cholesterol and
8.1% fat, by weight. Plasma cholesterol concentrations of low and high responders do not differ
on this diet. Most of the plasma cholesterol is carried by HDL, and ~30% of total plasma
cholesterol is carried by LDL [10]. After consuming the HCHF diet for at least 4 weeks, total
plasma cholesterol increases slightly (< 2-fold) in low responders, but dramatically in high
responders (>5-fold). HDL cholesterol levels of low and high responders show small (< 2-fold)
but significant increases. The increase in plasma cholesterol in high responders is mainly due
to an increase in VLDL and LDL (V+LDL) cholesterol such that the percentage of total plasma
cholesterol carried by V+LDL is increased to ~85% in response to diet. The increase in V+LDL
cholesterol on the HCHF diet alters the plasma lipid profile of high responding opossums to
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resemble more closely that of humans. Plasma triglyceride concentrations are relatively low
in low and high responders on the basal diet, and they are not responsive to dietary challenge.
The major lipoprotein is apoA-I and the minor lipoprotein is apoE in HDL particles from low
and high responders on both diets. ApoB is the major lipoprotein in V+LDL particles from low
and high responders on the basal diet and low responders on the HCHF diet. The V+LDL
particles from high responders on the HCHF diet are more heterogeneous, and they carry apoE
in addition to apoB [10].
Cholesterol absorption. Additional studies were conducted to determine whether low and high
responders differ in cholesterol absorption, which is one of the physiologic processes that
govern cholesterol homeostasis. Cholesterol absorption was measured by the fecal isotope
ratio method. On the basal diet, the percentage of cholesterol absorbed through the intestine
was ~60% in low and high responding opossums. On the HCHF diet, low responders reduced
the percentage of absorbed cholesterol by 50%, whereas high responders did not [63]. Several
genes that play a role in cholesterol absorption were analyzed to determine whether their
expression differed between low and high responders on the HCHF diet. Dietary cholesterol
increased expression of ABCG5 and ABCG8 in the small intestine of low and high responders
to limit absorption of cholesterol by transporting cholesterol from enterocytes to the intestinal
lumen; the extent of increase was similar in both strains of opossums. The NPC1L1 gene
transports cholesterol from the lumen into enterocytes, and the ACAT2 and MTP genes
facilitate chylomicron formation and secretion in the small intestine. These genes were
expressed at similar levels in low and high responders. Therefore, the difference in cholesterol
absorption between low and high responders is not due to differences in expression of genes
that regulate influx and efflux of cholesterol in the small intestine [64].
Bile acid synthesis. Liver is the other major site that controls cholesterol homeostasis. In the liver,
cholesterol is converted to bile acids, and bile acids and free cholesterol are secreted into bile
for disposal via fecal excretion. Bile acids are synthesized by two pathways, the classic pathway
and the alternate pathway. The rate-limiting enzyme in the classic pathway is 7α-hydroxylase.
The enzyme sterol 27-hydroxylase initiates bile acid synthesis in the alternate pathway and
catalyzes several oxidation reactions in the classic and alternate bile acid synthesis pathways
[65]. Low and high responders on the HCHF diet had similar 7α-hydroxylase activities but
differed in sterol 27-hydroxylase activities. Low responders had higher activity of hepatic
sterol 27-hydroxylase (14.1 ± 0.8 pmol/mg protein/min) compared with high responders (10.1
± 0.8 pmol/mg protein/min; P<0.01) [66]. Sterol 27-hydroxylase is encoded by the CYP27A1
gene. Expression of the CYP27A1 gene was also higher (2-fold) in low responders fed a high
cholesterol diet [64]. Given that sterol 27-hydroxylase catalyzes several reactions in the classic
and alternate pathways of bile acid synthesis, a reduction in enzyme activity was consistent
with lower concentrations of total bile acids in gall bladder bile of high responders (194 ± 19
mol/ml for high responders versus 244 ± 15 mol/ml for low responders; P=0.05) [66].
Biliary cholesterol and biliary phospholipids. Bile samples collected from gall bladders were
analyzed to determine whether there are any differences in the secretion of cholesterol into
bile by low and high responders fed the HCHF diet. The results revealed differences in biliary
cholesterol concentration and biliary phospholipid concentration in gall bladder bile. Choles‐
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terol concentration in the bile of low responders (5.7 ± 1.3 mg/ml) was higher than that of high
responders (1.3 ± 0.7 mg/ml; P<0.05). Similarly, phospholipid concentration in the bile of low
responders (29.7 ± 3.7 mg/ml) was also higher than that of high responders (6.9 ± 5.5 mg/ml
for high responders; P<0.05) [24]. Biliary cholesterol secretion is mediated by ABCG5, ABCG8
and NPC1L1. ABCG5 and ABCG8 transport cholesterol from the liver into bile [45] whereas
NPC1L1 transports cholesterol from the bile back into the liver [67]. Biliary phospholipid
secretion is mediated by ABCB4 [41,42]. The difference in biliary cholesterol and biliary
phospholipid secretion prompted an investigation of the expression of these genes in response
to dietary challenge in low and high responders. ABCG5 and ABCG8 mRNA levels did not
differ between low and high responding opossums, whereas NPC1L1 mRNA levels were
down-regulated in high responders [68]. There was no significant difference in ABCB4 mRNA
levels between low and high responders on the two diets [69]. Therefore, expression of
cholesterol and phospholipid transporter genes cannot explain differences in biliary lipid
concentrations.
Association of ABCB4 with hypercholesterolemia. Development of a genetic linkage map of
Monodelphis [70], coupled with the Monodelphis genome sequence [62], facilitated the identifi‐
cation of genes that predispose high responders to develop hypercholesterolemia on the HCHF
diet. Genome-wide linkage analyses on data from pedigreed opossums located two quantita‐
tive trait loci (QTL) influencing V+LDL cholesterol levels. The QTL on chromosome 1 influ‐
ences V+LDL cholesterol on the basal diet, and the QTL on chromosome 8 influences V+LDL
cholesterol on the HCHF diet [69]. One gene in the chromosome 8 QTL is ABCB4. Since ABCB4
plays a role in biliary secretion of phospholipids and cholesterol, lower levels of biliary lipids
in high responding opossums could be due to an impairment of ABCB4 function. We tested
this hypothesis by sequencing the ABCB4 gene to identify mutations and found two single
nucleotide polymorphisms (SNPs) that cause missense mutations in exons 2 and 7 of the
ABCB4 gene from high responders. In exon 2, Gly at amino acid 29 in allele 1 is substituted by
Arg in allele 2. In exon 7, Leu at amino acid 235 in allele 1 is substituted by Ile in allele 2. Allele
1 is predominant in the high responding strain, whereas allele 2 is predominant in the two low
responding strains [24,69].
Using a pedigree-based genetic association approach, matings of high responders with low
responders were carried out to produce F2 progeny in two different crosses (designated JCX
and KUSH6) to determine whether ABCB4 has an effect on response to dietary cholesterol.
Animals from both crosses were genotyped for the ABCB4 Ile235Leu polymorphism and
subjected to measured genotype analysis using plasma cholesterol data from a basal diet and
from a 4-week HCHF diet. The average concentration of plasma total cholesterol and V+LDL
cholesterol on the HCHF diet was highest in JCX animals homozygous for the ABCB4 ‘1’ allele,
intermediate in animals with the ABCB4 ‘1/2’ genotype, and lowest in animals homozygous
for the ABCB4 ‘2’ allele. A similar pattern was observed in animals from the KUSH6 cross. The
results showed that genetic variation in ABCB4 had a significant effect on variation in V+LDL
cholesterol levels in response to the HCHF diet, and implicated defects in biliary phospholipid
and biliary cholesterol secretion in causing diet-induced hypercholesterolemia in the opossum
model. However, it was apparent from the analysis that there is at least one additional gene
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that influences diet-induced hypercholesterolemia because some opossums that are homozy‐
gous for the missense mutations are not high responders [24,69].
Variations in the ABCB4 gene have not been shown previously to be associated with variations
in plasma LDL cholesterol in response to diet in other experimental animals or humans. ABCB4
mutations affect secretion of phospholipids, and clinical symptoms are due to production of
bile with a low phospholipid content which cannot prevent bile salts from damaging the
membranes of cells lining the bile ducts. Moreover, the phospholipid deficient bile has a high
cholesterol saturation index. In humans, ABCB4 variants that have a severe effect are associated
with progressive familial intrahepatic cholestasis type 3, a liver disease that often develops in
the first year of life. ABCB4 variants that have a moderate effect are associated with a gallstone
disease in adults known as low-phospholipid associated cholelithiasis, and a reversible form
of cholestasis known as intrahepatic cholestasis of pregnancy that develops in women during
the third trimester of pregnancy and resolves after delivery of their babies [71]. ABCB4
knockout mice lacking phospholipid transport function develop sclerosing cholangitis, which
progresses to metastatic liver cancer [72,73]. Mutations in the opossum ABCB4 gene do not
have a severe effect as high responders exhibit no adverse symptoms when the animals are
fed the basal diet. The reduction in biliary cholesterol and biliary phospholipids associated
with ABCB4 mutations leads to an increase in plasma V+LDL cholesterol when high responders
are challenged with the HCHF diet. However, a gene whose identity is still unknown seems
to be able to compensate for the reduction in biliary cholesterol secretion and rescues high
responders that are homozygous for the ABCB4 mutations from developing diet-induced
hypercholesterolemia. Identification of this gene will lead to a better understanding of the
process involving ABCB4 in controlling plasma LDL cholesterol concentration in response to
dietary cholesterol.
3.4. Pathologic features of high responders
Fatty livers. Dysregulated cholesterol homeostasis causes high responders to develop fatty
livers and atherosclerotic lesions. Cholesterol accumulates in the livers of high responders
as a result of impaired biliary cholesterol secretion. After 4 weeks of HCHF diet,  serum
levels  of  liver  enzymes  (alanine  aminotransferase,  aspartate  aminotransferase,  and  γ–
glutamyltransferase) and bilirubin were significantly elevated, indicating high responders
had liver injury. Histology revealed steatosis, inflammation and ballooned hepatocytes in
their livers after 8 weeks of HCHF diet. The pathologic condition in the liver worsened as
high responders continued to consume the HCHF diet.  In one study in which high and
low responders  were  fed  the  HCHF diet  for  24  weeks,  livers  of  high  responders  were
markedly  enlarged  compared  to  those  of  low  responders.  The  enlarged  livers  had  an
increase  in  free  cholesterol  (2-fold),  esterified  cholesterol  (11-fold)  and  triglycerides  (2-
fold), but no significant increase in free fatty acids. Low responders did not display any
significant  morphological  changes  in  the  liver  after  24  weeks  on  the  HCHF  diet.  Pro‐
longed HCHF dietary challenge caused high responders to develop fibrosis in addition to
steatosis, inflammation and ballooned cells. Liver fibrosis is a characteristic feature of the
severe  form  of  nonalcoholic  fatty  liver  disease  known  as  nonalcoholic  steatohepatitis.
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Expression of  a  set  of  hepatic  genes  associated with  inflammation,  oxidative  stress  and
fibrogenesis  was up-regulated in  high responders,  and the gene expression pattern was
consistent with the histopathological features in the livers of high responders [74].
Atherosclerotic lesions. Similar to humans, hypercholesterolemia leads to development of
atherosclerotic lesions in the arteries of high responding opossums. Low responding opossums
whose V+LDL cholesterol was below 75 mg/dl did not develop gross or histologically detect‐
able lesions after consuming the HCHF diet for one year. In contrast, high responding
opossums whose V+LDL cholesterol was over 500 mg/dl developed gross and histologically
detectable lesions after 40 weeks of HCHF diet. The opossum lesions were similar in histologic
characteristics to those observed in cholesterol-fed mouse models of atherosclerosis [23].
4. Non-human primate models
Non-human primate models stand out as the most biologically similar to humans in physio‐
logic and genetic characteristics of hypercholesterolemia [25]. This is because nonhuman
primates and humans share similar biochemical, anatomical and physiological characteristics,
including lipid synthesis and metabolism. Both humans and primates exhibit spontaneous and
diet-induced hypercholesterolemia [15] and develop atherosclerosis [11,75]. Commonly used
nonhuman primates include African green monkey (green monkey), rhesus monkey, cyno‐
molgus monkey and baboon. These species not only have a high degree of physiological
similarity with humans, but also have many of the same genes underlying relevant pheno‐
types. The size of nonhuman primates by comparison to mice enables the collection of tissue
and organ samples of equivalent sizes to humans, including arteries and hearts. It is important
to mention that great apes share greater similarities to humans than other nonhuman primates.
However, cost and ethical considerations prohibit use of great apes for most human disease
studies.
4.1. Nonhuman primate responses to HCHF diet
Nonhuman primates respond to HCHF diet as do humans. Most nonhuman primates respond
to HCHF diet by an increase in average total plasma cholesterol concentration ranging from
200-800 mg/dl with no change in weight [11,15]. Total plasma cholesterol levels positively
correlate with LDL cholesterol, VLDL cholesterol and triglyceride levels with no change in
HDL cholesterol levels. In addition, triglyceride concentration is positively correlated with
VLDL cholesterol and LDL cholesterol concentrations [15,25]. However, there are differences
among species and among individuals in response to HCHF diet in nonhuman primates.
Variation among species. Nonhuman primate species differ in their response to HCHF diet
challenges by exhibiting variation in plasma cholesterol [11,76]. Baboons and green monkeys
display moderate response with an average plasma cholesterol concentration of 204 and 275
mg/dl, respectively, while cynomolgus monkeys and rhesus macaque have the highest
response, 307 and 467 mg/dl, respectively [11,15,76]. The response of baboons is similar to that
of humans [11].
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In addition, green monkeys and baboons show unusual increases in HDL cholesterol levels in
response to HCHF diet compared to most nonhuman primate species [11,76]. The mechanisms
underlying the marked difference in response to HCHF diet for green monkeys and baboons
are not well understood. Sorci-Thomas et al. [76] compared the responses of green and
cynomolgus monkeys to HCHF diet. Because green monkeys develop modest hypercholes‐
terolemia compared to cynomolgus monkeys when challenged with HCHF diet, green
monkeys were fed diet with more cholesterol than cynomolgus monkeys to induce equivalent
extent of hypercholesterolemia in both species. Surprisingly green monkeys still had 2-3-fold
higher plasma HDL cholesterol and apoA-I concentrations than cynomolgus monkeys,
indicating that higher plasma HDL cholesterol in green monkeys was due to factors inde‐
pendent of level of dietary cholesterol. Further investigation indicated that green monkey
hepatic apoA-I and mRNA expression levels were respectively 2-fold and 3.7-fold higher, and
intestinal apoA-I mRNA level was 3.7-folder higher than in cynomolgus monkeys. These
observations indicate that factors that regulate mRNA transcription and post-transcription,
including microRNA (miRNA) gene regulation, may be determinants of resistance to HCHF
diet.
Variation among individuals. Similar to humans, nonhuman primates display variation among
individual animals of the same species in response to HCHF diet [77-80]. This variation is one
of the important features of nonhuman primate models that enables us to identify genetic
variants that predispose individuals to develop hypercholesterolemia.
a. Plasma lipoprotein cholesterol levels. The response of plasma cholesterol level to HCHF diet
differs among individuals. Baboons challenged with HCHF diet for 2 years exhibited an
increase in plasma cholesterol levels from 5 to 197 mg/dl [81]. Based on these observations,
McGill et al. selectively bred two lines of baboons with extreme plasma cholesterol levels;
low responders and high responders to HCHF diet. Subsequent studies have shown that
low and high responders differed in LDL cholesterol levels when challenged with HCHF
diet. High responders had approximately 2-fold higher plasma cholesterol than low
responders [11,80]. In addition, LDL apoB concentrations were 2-3-fold higher in high
responders compared with low responders [11]. This difference was due to higher
production of apoB in high responders. However, apoB mRNA levels did not differ
between low and high responders on HCHF diet, suggesting that apoB production is
regulated at the post-transcriptional level and is influenced by plasma cholesterol levels,
which differ between low and high responders.
McGill et al. [82] examined the effect of cholesterol or saturated fat on plasma cholesterol
response in low and high responders. The study revealed that high responders challenged
with diet containing high cholesterol (1.7 mg/kcal) displayed a higher percent increase of
LDL and VLDL cholesterol levels than low responders, and that there was no difference
in HDL cholesterol levels between high and low responders. The type of saturated fat,
corn or coconut oil in the diet did not influence plasma cholesterol variation between the
two lines of baboons. Genetic analysis revealed that genetic factors explained 57% of the
response to dietary cholesterol. These findings indicated that dietary cholesterol, and not
saturated fat, drives variation in plasma cholesterol in baboons.
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b. Expression of 27-hydroxylase. Nonhuman primates exhibit individual variation in the
synthesis of bile acids from cholesterol. Sterol 27-hydroxylase is an important enzyme for
bile acid synthesis in both the classic and alternate pathways. Kushwaha et al. [83]
measured plasma and hepatic 27-hydroxycholesterol levels, hepatic 27-hydroxylase
activity and mRNA levels in 12 low and 12 high responding baboons. Low responders
displayed higher 27-hydroxycholesterol levels, 27-hydroxylase activities and mRNA
levels than high responders when fed the HCHF diet but not when fed the chow diet.
These parameters were negatively correlated with LDL and VLDL cholesterol concentra‐
tions in low responders. These findings indicate that sterol 27-hydroxylase is induced by
HCHF diet and that the induction is higher in low responding baboons, resulting in higher
bile acid synthesis. Thus, the ability to induce sterol 27-hydroxylase influences LDL
cholesterol variation in baboons.
c. ApoE levels and LDL receptor expression. The liver clears excess plasma lipoprotein choles‐
terol through the LDL receptor and the LDL receptor-related protein. ApoE is a compo‐
nent of chylomicrons and most of the lipoproteins, and aids in receptor mediated-
clearance of plasma lipoprotein cholesterol [31]. A study in cynomolgus and green
monkeys fed an HCHF diet demonstrated that apoE concentrations were positively
correlated with total plasma cholesterol concentrations, plasma LDL cholesterol concen‐
trations and LDL particle size [12]. Since apoE is a high-affinity ligand for the LDL receptor
and the LDL receptor-related protein, plasma cholesterol clearance by the liver is expected
to increase when apoE levels are elevated, but this is not the case. A possible explanation
is that LDL receptors are down-regulated in hypercholesterolemic monkeys, and clear‐
ance of VLDL and LDL particles is impeded. ApoE-enriched LDL particles accumulate in
the plasma of hypercholesterolemic animals because VLDL particles are metabolized to
LDL particles rather than being removed from the circulation by the LDL receptor as in
monkeys with normal plasma cholesterol concentrations [12].
Together, these findings suggest that plasma cholesterol variation in nonhuman primates may
be influenced by the level of sterol 27-hydroxylase activity in the liver. A decrease in conversion
of cholesterol to bile acids may lead to an increase in plasma cholesterol, which in turn
decreases LDL receptor expression. As a consequence, the rate of clearance of plasma VLDL
and LDL cholesterol is reduced and circulating levels of LDL cholesterol are elevated.
4.2. Genetic mechanisms that influence individual variation in plasma cholesterol levels
Baboon genetic resources to study lipid metabolism. The baboon is the most commonly used primate
model for genetic studies of complex traits and susceptibility to complex diseases [14]. The
Southwest National Primate Research Center (SNPRC) at Texas Biomedical Research Institute
maintains approximately 1,500 living baboons for biological research. These baboons have
been used to develop nonhuman primate genomic resources to study responses to environ‐
mental factors, such as diet, and how these factors interact with genomic factors in causing
complex diseases or disorders. In addition, SNPRC maintains an extensive pedigree database
consisting of 16,000 baboons across seven generations. This is the largest nonhuman primate
pedigree in the world. The pedigreed population includes approximately 384 founders of olive
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(P. h. anubis) and yellow (P. h. cynocephalus) baboons, and their hybrid descendants. These
resources provided a unique opportunity to map baboon genes, resulting in the first ever
nonhuman primate linkage map [84,85]. In addition, tissues and blood samples have been
collected from 8,000 baboons, and DNA, serum and buffy coats from 4,000 animals [14].
Genetic factors for hypercholesterolemia in baboons. Baboon response to HCHF diet is modest,
similar to the response of humans. Because of this similarity as well as other baboon charac‐
teristics that mimic human characteristics, numerous studies have utilized baboon resources
available at SNPRC to understand how genetic variation influences lipoprotein cholesterol in
response to diet. This initiative started more than three decades ago when scientists at the
Texas Biomedical Research Institute observed differential response of baboons to HCHF diet
[81]. These observations led to selective breeding and characterization of distinct phenotypes
of baboons and revealed that differential response to HCHF diet is heritable [86,87].
Attempts to find the major genes influencing plasma cholesterol in response to dietary
challenge revealed that polymorphisms in the LDL receptor gene contributed only 6% of the
variation [88], suggesting that lipid response to HCHF diet is multigenic. Hypercholesterole‐
mia is a complex disorder plausibly influenced by complex genetic networks. Therefore, to
elucidate the mechanisms that underlie cholesterol variation, a system biological approach is
most appropriate. Using available pedigree and genotypic information for more than 2,400
baboons, important lipid/lipoprotein-related QTL have been identified [27,89,90]. In addition,
improved Next Gen Sequencing techniques for RNA and DNA sequencing and genetic
network analyses have enabled understanding of genes encoding these QTL.
Studies were undertaken to interrogate the QTL to discover gene, genetic variants and
functional mechanisms that influence variation in response to diet in baboons. In one study,
four novel candidate genes (TENC1, ACVR1B, ERBB3, DGKA) were identified that encode a
QTL for LDL cholesterol concentration variation. This QTL overlaps multiple other QTL for
LDL related traits, including particle size, suggesting that these genes have pleiotropic effects
[13]. TENC1 was downregulated while ACVR1B, ERBB3 and DGKA were upregulated in
response to HCHF diet. The protein products of all four genes are central molecules for a single
pathway, affirming that multiple genes influence LDL cholesterol variation. Interestingly these
genes are associated with cancer in the AKT/GSK3B signaling pathway [91]. Several studies
have alluded a link between cancer, hypercholesterolemia and atherosclerosis [92-95], but the
link is not well understood. One aspect that is clear is that cholesterol is intertwined in the
etiology of cancer and atherosclerosis. In addition, tumorigenesis thrives by the ability to alter
important biological processes, including regulation of cholesterol levels. For cancer cells to
proliferate uncontrollably, essential cell components, such as cholesterol must be available for
plasma membrane synthesis. In order to meet the demand for cholesterol, pathways regulating
cellular cholesterol homeostasis are altered in cancer cells.
Other studies have investigated the role of miRNA in LDL cholesterol variation in baboons
[13,80]. miRNAs were hypothesized to regulate genes encoding variation in LDL cholesterol
in response to HCHF diet. Hepatic miRNA expression profiling in low and high LDL choles‐
terol half–sibling baboons by RNA sequencing revealed 226 miRNAs were differentially
expressed (160 downregulated and 66 upregulated) between low and high responders in
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response to HCHF diet. In order to identify molecular mechanisms that may regulate LDL
cholesterol variation, these miRNAs were overlaid onto gene networks that differ between low
and high baboon responders. Seven miRNAs were inversely expressed with respect to the four
candidate genes. Together, these findings demonstrate that hepatic miRNAs are responsive to
diet, and that response differs among baboons with different plasma LDL cholesterol levels.
4.3. Nonhuman primates and atherosclerosis, the clinical endpoint of hypercholesterolemia
Atherosclerosis, a complex progressive disease, is the leading cause of mortality and morbidity
in developed countries [96,97]. The clinical end-point of atherosclerosis is cardiovascular
disease primarily caused by thickening and/or occlusion of coronary arteries. Atherosclerotic
heart disease is the leading cause of death in the world and is projected to remain the single
leading cause of death by 2030 [98].
Atherogenesis is similar in nonhuman primates and humans. Atherogenesis is a multifactorial
process. Initial events during atherogenesis include deposition of modified or oxidized
cholesterol (ox-cholesterol) in the artery wall, resulting in endothelial dysfunction; adhesion
of circulating monocytes onto the endothelium; entry of ox-cholesterol and monocytes into the
intima layer of the artery; engulfment of ox-cholesterol by monocytes and transformation into
macrophages and foam cells; production of pro-inflammatory cytokines and connective
matrix; conversion and proliferation of smooth muscle cells; cell apoptosis; and intima
thickening. During these processes, atherosclerotic lesions, which are grossly and microscop‐
ically heterogeneous, develop on the intimal arterial surface. In nonhuman primates, as in
humans, the initial lesions are flat fatty streaks, which are not elevated on the intimal surface,
containing predominately foam cells derived from monocytes and smooth muscle cells filled
with minimal lipid. These lesions advance to raised fatty streaks that are characterized by lipid-
filled foam cells. Raised lesions may progress to advanced fibrous plaques with lipid cores and
accumulated connective matrix [26,75,99].
Lipoprotein cholesterol and atherosclerosis. Nonhuman primates provide a unique opportunity
not only to understand the factors that underlie differential response to HCHF diet but the link
between diet response and development of atherosclerosis in humans. In both nonhuman
primates and humans, dyslipidemia is associated with atherosclerosis. High levels of non-HDL
cholesterol, including LDL cholesterol, VLDL cholesterol and triglycerides, induced by HCHF
diet are positively correlated with the extent and severity of atherosclerosis while HDL
cholesterol is negatively correlated [75]. This implies that HCHF diets indirectly influence
atherogenesis through induction of hypercholesterolemia. Another study with baboons
revealed that plasma HDL1 levels are negatively correlated with extent and severity of
atherosclerosis [11]. These results are consistent with results from human studies that indicate
plasma lipoprotein cholesterol levels and lipoprotein subclasses are indicators of the extent of
atherosclerosis [100]. Stevenson et al. [12] observed in cynomolgus monkeys that an increase
in apoE correlates with extent of atherosclerosis, suggesting that apoE may represent an
atherogenic feature of diet-induced hypercholesterolemia.
Arterial distribution of atherosclerosis. Atherosclerosis in nonhuman primates and humans
displays a distinctive topographical distribution in the arterial system. The extent and severity
of the disease is greater in the abdominal and common iliac arteries than in the thoracic and
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aortic arch, whereas flat lesions are more abundant in thoracic and aortic arch in nonhuman
primates and humans [11,26]. It is hypothesized that the distinct localization of atherosclerotic
lesions is a consequence of hemodynamic stress induced by blood flow; and anatomic, cellular,
or biochemical variations in the arterial wall, particularly in the endothelium. These hypoth‐
eses are consistent with observations of more abundant lesions in branches and bifurcations
of medium-sized arteries, including abdominal and common iliac arteries in nonhuman
primates [101]. However, the mechanisms underlying the varied distribution of atherosclerosis
in both humans and nonhuman primates are not well understood.
Variation among species and individuals in development of atherosclerosis. Nonhuman primate
species display variation in susceptibility to developing atherosclerosis. Paralleling the
different responses to HCHF diet, rhesus and cynomolgus monkeys are more susceptible to
atherosclerosis [102] than green monkeys and baboons, which develop moderate atheroscle‐
rosis [103] as do humans [11]. Individuals within any one species also display differential
susceptibility to atherosclerosis. High responders to HCHF diet develop more severe athero‐
sclerosis than low responders, consistent with differential levels of plasma non-HDL choles‐
terol [26]. It is this variation that is critical for identification of genetic factors underlying
variation in atherosclerosis development. This variation is heritable [104] and may correspond
to genetic variation that underlies observed plasma cholesterol variation in response to HCHF
diet.
5. Conclusion
ApoE deficient mice, generated by gene targeting, have a lipoprotein profile similar to humans
in that most of the plasma cholesterol is carried on VLDL and IDL particles rather than HDL
particles as in non-genetically modified mice. ApoE-/- mice have elevated levels of plasma
cholesterol even on a chow diet and develop atherosclerotic lesions spontaneously. Advanced
lesions with plaque rupture that resemble those in humans are frequently observed in apoE-/-
mice fed an HCHF diet, and these mice are used for developing drugs to reduce atherosclerosis.
A nonbiliary pathway for cholesterol excretion in humans was suggested more than five
decades ago based on measurement of intestinal cholesterol secretion from patients with bile
duct obstruction. This finding was largely ignored because hepatobiliary secretion is believed
to be the only route to dispose of cholesterol in feces. Observations from studies using several
genetically modified mice (G5G8-/-, Abcb4-/- and Npc1l1-LiverTg) that have severe defects in
biliary cholesterol secretion, but normal or even increased fecal neutral sterol excretion,
prompted several groups of researchers to investigate the TICE pathway. They reported that
TICE accounts for 20%-30% of fecal neutral sterol excretion. However, mechanistic details of
TICE still remain unknown. Because cholesterol excretion is an important process to eliminate
cholesterol from the body, stimulation of TICE by pharmacological agents may be a novel
therapeutic strategy to limit atherogenesis.
Studies using genetically modified mice have shown that they are indispensable for advancing
our knowledge of the genes and pathways that govern cholesterol homeostasis, as well as for
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developing pharmacological agents to treat atherosclerosis. Traditional gene targeting using
embryonic stem cells is a complex and time-consuming procedure to produce mutant mice
and is limited to targeting one gene at a time. Mice carrying mutations in multiple genes are
produced either by sequential gene targeting or intercrossing mice with a single mutation. The
CRISPR (clustered regularly interspaced short palindromic repeat)-Cas9 (CRISPR-associated
nuclease 9) system is a new and more efficient genome engineering technology [105]. It allows
targeting multiple genes at the same time by direct co-injection of RNA encoding the Cas9
nuclease and several gene-specific guide RNA into a one-cell embryo to generate mice with
multiple modified genes [106]. Application of the CRISPR/Cas system will accelerate the
production of mouse models carrying multiple modified genes to study complex disease such
as hypercholesterolemia.
High responding opossums have naturally occurring genetic variants that predispose them to
develop hypercholesterolemia when challenged with an HCHF diet. At least two major genes
control the plasma cholesterol response to dietary challenge in high responding opossums.
One has been identified as the ABCB4 gene. Mutations in ABCB4 impair the ability of high
responding opossums to secrete phospholipids into the bile. Because secretion of cholesterol
into bile requires phospholipids, biliary cholesterol secretion is also impaired in high respond‐
ing opossums. As a consequence, plasma V+LDL cholesterol becomes elevated in high
responders, and free and esterified cholesterol accumulates in their livers. However, some
opossums that are homozygous for the ABCB4 mutations are resistant to diet-induced
hypercholesterolemia. The compensatory mechanism that allows these opossums to overcome
the defect in biliary cholesterol secretion is not known. In light of the finding of a nonbiliary
route of cholesterol excretion that functions in normal mice as well as in mice that have very
low biliary cholesterol secretion, cholesterol excretion by the nonbiliary route may compensate
for the defect in biliary excretion in opossums that are homozygous for the ABCB4 mutations.
Phylogenetic similarities between humans and nonhuman primate models are core aspects for
consideration in investigations of environmental and genetic factors that contribute to complex
diseases/disorders, including hypercholesterolemia and atherosclerosis. Moreover, like
humans, nonhuman primates exhibit diet-induced hypercholesterolemia and naturally
develop atherosclerosis, making it possible to identify phenotypic variations without altering
genetic background as is required for this line of research with mice. In addition, environ‐
mental factors, including diet, can be controlled for a prolonged period of time, invasive and
terminal experiments can be conducted, and tissues and organs can be easily collected. These
research activities are not attainable when working with human subjects.
Recent scientific advances have led to discovery of therapeutic regimes, including statins for
lowering LDL cholesterol and retarding the development of atherosclerosis [107]. However,
these therapies are limited by side effects and ineffectiveness in some individuals [108,109].
Thus, there is a need for continued searching for novel therapeutic agents. Diet-induced
hypercholesterolemia in nonhuman primates provides an opportunity 1) to identify lipid
profiles important for the development of atherosclerosis in primates in a controlled environ‐
ment, 2) to identify variation in responses to diet, and 3) to assess progression of and variation
in development of atherosclerosis in response to dietary cholesterol and saturated fat. Identi‐
fication of these variations is essential for genetic analysis to develop novel therapeutic agents
Hypercholesterolemia20
for lowering plasma cholesterol and biomarkers for detection of early atherosclerosis, a
precursor for cardiovascular disease.
Nonhuman primate genetic resources for studying complex diseases are becoming increas‐
ingly sophisticated and available at SNPRC and Texas Biomedical Research Institute. These
resources enable scientific collaborations to study human diseases using multidisciplinary
approaches. Significant steps have been achieved in the identification of genetic causes of
hypercholesterolemia and atherosclerosis, including discovery of QTL and genes and gene
variants that influence plasma LDL and HDL cholesterol levels, and triglyceride levels.
Further improvement and enhancement of unique genetic resources for research with mice,
laboratory opossums, and nonhuman primates will be critical for future research aimed at
understanding genetic and epigenetic factors influencing human health and disease.
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